DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20171967

Evaluation of vitamin D3 in patients of polycystic ovary syndrome and their correlation

Rooplekha Chauhan, Sonal Sahani, Ankita Garg

Abstract


Background: Polycystic ovary syndrome (PCOS) is enigma faced by young females since the onset of urbanization. As on day, PCOS is the most common endocrine disorder in the women of reproductive age affecting 4-10%. This study done to measure serum vitamin D3 levels of PCOS patients and to identify its association with factors associated with various symptoms and signs in PCOS.

Methods: Institutional based prospective observational study conducted on 70 patients of PCOS, both suspected and already diagnosed, attending gynecology OPD of Department of obstetrics and gynecology of NSCB Medical College Jabalpur from 1 March 2015 to 31 August 2016. Diagnosis of PCOS was made by Rotterdam 2003 criteria. A detailed assessment was done and preformed proforma was filled. Serum Vitamin D3 levels were estimated by standard lab technique ‘Liquid Chromatography Tandem Mass Spectrometry’ and categorized into vitamin D3 sufficient >30ng/dl, insufficient 20-29ng/dl and deficient <20ng/dl. Categorical data was coded numerically before the analysis. For comparison of frequency distribution chi square test or fisher’s exact test were applied as appropriate.

Results: Prevalence of Vitamin D3 deficiency in patients of PCOS was found to be 84.3%.

Conclusions: The present study concludes that there is correlation between vitamin D3 and PCOS, screening and correction of vitamin D3 deficiency may prevent PCOS and its manifestations. Hence, it is speculated that improvement of vitamin D3 levels at a younger age can contribute to prevention of PCOS.


Keywords


Polycystic ovary syndrome, Rotterdam criteria, Vitamin D3 deficiency

Full Text:

PDF

References


Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis 1. Endocrine Rev. 1997;18(6):774-800.

Diamanti-Kandarakis E, Kouli C, Bergiele A, Filandra F, Tsianateli T, Spina G, et al. A Survey of the Polycystic Ovary Syndrome in the Greek Island of Lesbos: Hormonal and Metabolic Profile. J Clini Endocrinol Metab. 1999;84(11):4006-11.

Zawadzki JK, Dunaif A. In:Dunaif A, ed. Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1995: 377-84.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88.

Holick M. Vitamin D Deficiency. New England J Medic. 2007;357(3):266-81.

Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intrnal Medic. 2008;264(6):599-609.

Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids. 1999;64(6):430-5.

Firouzabadi R, Aflatoonian A, Modarresi S, Sekhavat L, Mohammad Taheri S. Therapeutic effects of calcium and vitamin D supplementation in women with PCOS. Complementary Therap Clini Pract. 2012;18(2):85-88.

Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin H, et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280(4):559-63.

Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S et al. Low Serum 25-Hydroxyvitamin D Concentrations are Associated with Insulin Resistance and Obesity in Women with Polycystic Ovary Syndrome. Experment Clini Endocrinol Amp Diab. 2006;114(10):577-83

Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber T, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. European J Endocrinol. 2009;161(4):575-82.

Mahmoudi T, Gourabi H, Ashrafi M, Yazdi R, Ezabadi Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril. 2010;93(4):1208-14.

Lagunova Z, Porojnicu A, lLindberg F, Hexeberg S, Moan J. The Dependency of Vitamin D Status on Body Mass Index, Gender, Age and Season. Anticancer Res. 2009;29(9):3713-20.

Li HW, Brereton R, Anderson R, Wallace A, Ho C. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metab. 2011;60(10):1475-81.

Lou Y, Murtola T, Tuohimaa P. Regulation of aromatase and 5α-reductase by 25-hydroxyvitamin D3, 1α,25-dihydroxyvitamin D3, dexamethasone and progesterone in prostate cancer cells. J Steroid Biochem Mol Biol. 2005;94(1-3):151-7.

Thomson R, Spedding S, Buckley J. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol. 2012;77(3):343-50.

Figurová J, Dravecká I, Javorský M, Petríková J, Lazúrová I. Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities. Wiener klinische Wochenschrift. 2015;19:1-8.

Rashidi B, Haghollahi F, Shariat M, Zayerii F. The Effects of Calcium-Vitamin D and Metformin on Polycystic Ovary Syndrome: A Pilot Study. Taiwanese J Obstet Gynecol. 2009;48(2):142-7.

Toossi P, Azizian Z, Yavari H, Fakhim TH, Amini SH, Enamzade R. Serum 25-hydroxy vitamin D levels in patients with acne vulgaris and its association with disease severity. Clini Cases Mineral and Bone Metab. 2015;12(3):238.

Slyper AH, Kashmer L, Huang WM, Re’em Y. Acanthosis nigricans, vitamin D, and insulin resistance in obese children and adolescents. J Pediatr Endocrinol Metab. 2014;27(11-12):1107-11.